Online inquiry

IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9385MR)

This product GTTS-WQ9385MR is a type of mRNA modified with 5-Methoxy-UTP, which ecodes the monoclonal antibody that targets IL2R gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000417.3; NM_000878.5; NM_000206.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559; 3560; 3561
UniProt ID P01589; P14784; P31785
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ9385MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14453MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ13659MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ11281MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI4893
GTTS-WQ15769MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA WX-G250
GTTS-WQ1194MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABP 980
GTTS-WQ9027MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ14062MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-3918
GTTS-WQ11519MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MFGR1877S
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW